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ABSTRACT 
Introduction: Breast cancer is among the most common malignancies of human around the world. 
Millions of cases of cancer worldwide occur annually, which, if detected in a timely manner, are easier 
to treat and can be conveniently controlled. In 2008, about 1,384,155 breast cancer cases were detected 
worldwide, with about 459,000 of them deceased.Method:MTT assay was performed to evaluate cell 
proliferation.The BCL2 gene is an inhibitor of apoptosis that prevents the release of cytochrome C from 
mitochondria and leads to inhibition of various apoptosis stimuli. Due to the importance of this gene in 
the apoptotic process, the level of BCL2 gene expression under treatment of Cisplatin and Centaurea 
Behen agents for 24 hours and 48 hours was evaluated in this research,using the Real time-PCR method. 
It is noteworthy that Cisplatin as a DNA binding agent may be effective in treating breast 
cancer;moreover, some studies have shown that Centaurea Behenplant has an antioxidant effect that can 
be a preventive factor in cancer.Results: The results obtained related to Cisplatin showed that IC50 for 
cells treated with Cisplatin for 24 hours was about  2.91 mg/ml while IC50 for cells treated with 
Cisplatin for 48 hours was about 1.77 mg/ml. Similarly, results obtained related to Centaurea 
Behenherbal extract showed that IC50 for cells treated with Centaurea Behen for 24 hours was about 
9.64 mg/ml while IC50 for cells treated with Centaurea Behen for 48 hours was about 7.85 
mg/ml.Results showed that the expression level of gene under treatment of the Cisplatinand Centaurea 
Behenhas decreased compared to the non-treatment state, so this expression reduction showed a 
significant difference between samples group and control group . 
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 INTRODUCTION 
     Cancer is one of the chronic and non-
contagious malignant diseases, which is 
considered as a serious problem affecting the 
health of the community. Breast cancer which 
accounts for 23% of all cancers in women is the 
most common cancer and malignancy among 
women[1, 2]. Breast cancer is a major public 
health concern, with 1,384,155 estimated new 
cases from population-based cancer registries in 
2008 worldwide with nearly 459,000 related 
deaths[3, 4]. In 2002, there were an estimated 
129,000 breast cancer–related deaths among 
women across Europe. By 2050, the incidence 
of breast cancer in women is predicted to reach 
approximately 3.2 million new cases 
worldwide[5].Breast cancer is caused by very 
distinct clinical, morphological and molecular 
cases[6]. Breast cancer is divided into five 
subtypes: Luminal A, Luminal B, human 
epidermal growth factor receptor 2 (HER2/ 
ERBB2)-positive, basal-like, and normal-like 
breast cancer[7, 8]. Luminal A and Luminal B 
are estrogen receptor (ER) positive, but luminal 
B cancer has a weaker outcome[9]. One of the 
processes involved in cancer is apoptosis.  
 




Apoptosis has been shown to be controlled by 
many external cellular and intracellular factors, 
one of which is BCL2 gene (Apoptosis 
inhibitors)[10]. BCL2 has an anti-apoptotic 
effect that prevents the release of cytochrome C 
from mitochondria which leads to inhibition of 
various apoptosis stimuli. Bcl-2 family 
members are essential for the conservation of 
major organ systems and mutations affecting 
them are implicated in cancer[11]. 
Pharmacological studies on breast cancer can 
be cited to Cisplatin[12].Cisplatin is one of the 
factors used in chemotherapy; and yet, it  is not 
always used to treat breast cancer.Cisplatin as a 
DNA cross-linking agent may be effective in 
the treatment of hereditary BRCA1-mutated 
breast cancer[13, 14]. 
Throughout time, numerous plants containing 
alkaloids have been used for treating mental 
problems.Alkaloids have a strong link with 
central nervous system (CNS) 
receptors.Recently, it has been shown that 
flavonoids also may be involved with enzymes 
on brain receptor systems and have different 
effects on the CNS[15]. Flavonoids,in addition 
to effects on CNS have many biological effects. 
They have attracted attention as free radical 
scavengers with antioxidant 
activity[16].Various studies have shown the 
presence of flavonoids in Centaurea 
species[17]. Therefore, the effect of herbal 
medicine Centaurea Behen with antioxidant 
properties could be involved in preventing 
cancer. In this study, the effect of Cisplatin and 
Centaurea Behen extract was evaluated on 
BCL-2 gene expression level in breast cancer 
tissues. 
 
MATERIAL AND METHODS 
Preparation of Centaurea BehenExtract 
     Centaurea Behenwas purchased from 
Biological Resource Center, Tehran, Iran. 
The ethics approval number is 
15930553952022. The extraction method was 
maceration. In this case, 20 grams of each plant 
sample was immersed in a 300 ml of 80% 
ethanol. The plant was soaked in solvent for 6 
days, then incubated at 37 ° C until complete 
evaporation. The final extracts were stored in 
aluminum-coated containers until use. 
Cell Culture  
     MCF-7 (human breast cancer cell line) was 
purchased from Biological Resource Center, 
Tehran, Iran. The cells were cultured in RPMI-
1640 with 500 µl of Pen/Strep (Penicillin 100 
u/ml – Streptomycin 100 µg/ml) and 5 ml of 
FBS; then,Cell Suspensioncultures 
wereincubated in 5% CO2 at 37°C. 
Preparation of Extracts with Different 
Concentrations 
     The MCF-7 cells were incubated with 
different concentrations of Centaurea 
Behenextract (61, 63 and 64 mg in 1 ml of 
RPMI 1640, respectively) for 24 and 48 hrs.The 
cells were treated with different concentrations 
of Cisplatinfor positive control. 
Cell Proliferation Assay 
     MTT assay was performed to evaluate cell 
proliferation where 10
4 
cells were seeded in 96 
well plates and incubated with different 
concentrations of Centaurea Behenextractor 
different concentrations of Cisplatin for 24 and 
48 hrs. Then, 20 μl MTT(3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) was added to each well, and the plates 
were incubatedin 5% CO2 at 37°C for 4 hrs. 
Then, the medium was replaced with 150 μl of 
2-Propanoland the absorbance was recorded at 
570 nm. 
Treatment of MCF-7 cells with Cisplatin and 
Centaurea Behen herbal extract, RNA 
extraction and cDNA Synthesis 
     The MCF-7 cells were treated with different 
concentrations of Centaurea 
Behenherbalextract and Cisplatin for 24 and 48 
hrs. Total RNA was isolated from each 
cellthrough using RNX-Plus (Cinnagene ® Cat. 
no.: RN7713C, Iran) according to the 
manufacturer’s specifications. The 
concentration of total RNA was determined by 
spectrophotometry (ND-1000, Wilmington, 
DE). cDNA synthesis was performed using the 
Prime Script RT reagent kit (Perfect Real Time) 
RR037A (Takara, Japan) according to the 
manufacturer’s specifications. The obtained 
cDNAs were stored in -80℃ until use. 
Real-time Quantitative PCR 
     Real-time PCR was performed in a 20-μl 
reaction, containing 10-μl of RealQ Plus 2x 
Master Mix Green High ROX™ (Ampliqon, 
Denmark), 2-μl of cDNA (20 ng/ µl), 6-μl of 
H2O, 1-μl of the forward primer and 1-μl of 
reverse primers (10 Pmol/μl concentration). 
Real-time PCR amplifications were done as 
follows: PCR amplification was set to an initial 
95°C for 15 min and then for BCL2 gene, a 
 




total of 35 cycles, 94°C for 15 seconds, 60°C 
for 30 seconds and 72°C for 30 seconds. For 
internal control, we used Beta-actin and all 
samples were analyzed in duplicate. The 
primers used for real-time PCR are listed in 
Table 1. 
 
Table 1. Primer sequences used for real-time PCR. 











     Gene expression was calculated using the 
comparative threshold cycle (2
-△△CT) method 
using REST© (Relative Expression Software 
Tool, Germany). A P value <0.05 was 
considered statistically significant for all tests. 
 
RESULTS 
Assessment of cell viability 
     The MCF-7 cells were treated with different 
concentrations of Centaurea Behen herbal  
extract and Cisplatin for 24 and 48 hrs. Results 
obtained related to Cisplatin showed that IC50 
for cells treated with Cisplatin for 24 hours was 
about  2.91 mg/ml while IC50 for cells treated 
with Cisplatin for 48 hours was about 1.77 
mg/ml. Likewise, results obtained related to 
Centaurea Behen herbal extract showed that 
IC50 for cells treated with Centaurea Behen for 
24 hours was about 9.64 mg/ml while IC50 for 
cells treated with Centaurea Behen for 48 hours 
was about 7.85 mg/ml. (Figure.1 Shows the 




Figure1.  The graph (A) related to treatment with Cisplatin for 24 hours, (B) related to treatment with Cisplatin for 48 hours, 
(C) related to treatment Centaurea Behen herbal extract for 24 hours and (D) related to treatment Centaurea Behen herbal 
extract for 48 hours. 
 
 





Checking Level Expression of BCL2 Gene 
Under Treatment by Cisplatin for 24 and 48 
Hours 
     Results obtained in non-treatment status 
showed that there was no significant difference 
between the level of BCL2 gene expression in 
sample group (no treatment) compared to 
control group (P=0.91). Results of under 
treatment for 24 hours by Cisplatin showed that 
the expression level of BCL2 gene has 
decreased so that there was significant 
difference between the level of BCL2 gene 
expression in sample group compared to control 
group (P=0.013). Also, the results of 48 hours 
treatment with Cisplatin showed that BCL2 
gene expression level has decreased compared 
with level expression of this gene in 24 hours 
status, so there was a significant difference 
between the level of expression of BCL2 gene 
expression in sample group compared to control 
group (P=0.001). (Fig.2 and Fig.4 show the 
results of BCL2 gene expression level by 
treatment with Cisplatin). 
 
                               Figure2.  Difference in the level of gene expression BCL2 under the treatment with Cisplatin 
 
Checking level expression of BCL2 gene 
under treatment by Centaurea Behen herbal 
extract for 24 and 48 hours 
     Results of under treatment for 24 hours by 
Centaurea Behen herbal extractdemonstrated 
that the expression level of BCL2 gene has 
decreased. Therefore, there was a significant 
difference between the level of BCL2 gene 
expression in sample group comparedwith 
control group (P=0.02). Also, the level of BCL2 
gene expression in the 48-hour treatment period 
with Centaurea Behen herbal extract has 
decreased with cpmpared to the 24-hour status 
(P=0.001). (Fig.3 and Fig.4 show the results of 
BCL2 gene expression level by treatment with 
Centaurea Behen). 
 
                     Figure3.  Difference in the level of gene expression BCL2 under the treatment with Centaurea Behen 
 






Figure4. The difference in the level of BCL2 gene expression under treatment with Cisplatin 
and Centaurea Behen agents 
 
DISCUSSION  
     Herbal extracts usually exert their effects on 
the cancer cells through direct action on tumor 
cells or with increased immune responses. 
Using herbal extracts may cause beneficial 
effects, such as reduction of the cytotoxic 
effects of chemotherapy in patients with cancer. 
In the onset and progression of breast cancer, 
many factors and genes are involved. Among 
them, the genes which are involved in apoptosis 
play a significant role in the treatment and 
survival of patients. It has been shown that the 
Bcl-2 gene plays an important regulatory role in 
apoptosis. This gene is a cellular protein that 
inhibits apoptosis in normal tissues, including 
breast tissues. In the present study, the extract 
of Centaurea Behen and Cisplatin were assessed 
on Bcl-2 gene expression in MCF-7 cell line;it 
has been manifested that Bcl-2 gene expression 
down regulated 2.42 and 4.4 fold, when treated 
with Centaurea Behen, and 9.7 and 11.62 fold, 
when treated with Cisplatin during 24h and 48h, 
respectively. Considering the results of this 
study, the Centaurea Behen extract and 




     The present study shows that the Centaurea 
Behen extract and Cisplatin could induce 
apoptosis in MCF-7 cell line through reducing 
expressionof Bcl-2 gene. Due to the natural 
properties of Centaurea Behen extract compared 
to chemical Cisplatin, the use   of    this    herbal  
 
 
product along with other anti-cancer drugs 
could be more effective. 
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